Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer

Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer
Women with BRCA-mutated relapsed serous ovarian cancer who received AstraZeneca’s Lynparza (olaparib) as a maintenance therapy after responding to platinum-based chemotherapy took an average 14 months to see their disease progress, compared to 7.3 months among patients receiving placebo. Additionally, the quality of life (QoL) in the two groups was similar, according to ratings by the patients. The results came from the SOLO-2 Phase 3 clinical trial (NCT01874353), summarized in the presentation "Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial." The study, presented at the June 2-6 American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, evaluated patients' time to disease progression (PFS), quality of life (QoL) and time without symptoms of disease or toxicity (TWiST), along with the safety profile. Patients were observed for up to 27 months after the beginning of the trial, which randomized 295 patients into test and placebo groups. All women had been treated at least twice with platinum-based chemotherapy and had partially or completely responded to their most recent treatment. The women had BRCA1 or BRCA2 breast cancer gene mutations in their DNA. BCRA proteins normally repair DNA, but mutations in the genes that code for them can leave DNA without repair, ca
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *